Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
BS-02 is a randomised, double-blind, placebo-controlled, phase 1 dose escalation study to
assess the safety, tolerability and immunogenicity of FluBHPVE6E7, in women infected with
HPV-16. with cervical cytological evaluation negative for intraepithelial lesion or
malignancy (NILM), atypical squamous cells of undetermined significance (ASC-US), low grade
squamous intraepithelial lesion (LSIL), or low-grade cervical intraepithelial neoplasia
(CIN1).